Troy C. Lund

TL;DR: It is reported here that cells co-purifying with mesenchymal stem cells—termed here multipotent adult progenitor cells or MAPCs—differentiate, at the single cell level, not only into meschymal cells, but also cells with visceral mesoderm, neuroectoderm and endoderm characteristics in vitro.

TL;DR: MPCs that proliferate without obvious senescence under clinically applicable conditions and differentiate at the single-cell level not only into mesenchymal cells but also cells of visceral mesoderm may be an ideal source of stem cells for treatment of genetic or degenerative disorders affecting cells of mesodermal origin.

TL;DR: MAPCs, derived from normal human, mouse, and rat postnatal bone marrow primitive, multipotent adult progenitor cells, can differentiate into cells with morphological, phenotypic, and functional characteristics of hepatocytes, and may be an ideal cell for in vivo therapies for liver disorders or for use in bioartificial liver devices.

TL;DR: Early results of this study suggest that Lenti‐D gene therapy may be a safe and effective alternative to allogeneic stem‐cell transplantation in boys with early‐stage cerebral adrenoleukodystrophy.

TL;DR: Increased C7 deposition and a sustained presence of donor cells were found in the skin of children with recessive dystrophic epidermolysis bullosa after allogeneic bone marrow transplantation, and further studies are needed to assess the long-term risks and benefits of such therapy in patients with this disorder.